Wietzke-Braun Perdita, Braun Felix, Schott Peter, Ramadori Giuliano
Medizinische Universitatsklinik, Abteilung Gastroenterologie, Robert-Koch-Strabetae 40, 37075 Goettingen, Germany.
World J Gastroenterol. 2003 Apr;9(4):745-50. doi: 10.3748/wjg.v9.i4.745.
To evaluate the potential of laparoscopy in the diagnosis of cirrhosis and outcome of interferon treatment in HCV-infected patients.
In this retrospective study, diagnostic laparoscopy with laparoscopic liver biopsy was performed in 72 consecutive patients with chronic HCV infection. The presence or absence of cirrhosis was analyzed macroscopically by laparoscopy and microscopically by liver biopsy specimens. Clinical and laboratory data and outcome of interferon-alfa treatment were compared between cirrhotic and noncirrhotic patients.
Laparoscopically, cirrhosis was seen in 29.2 % (21/72) and non-cirrhosis in 70.8 % (51/72) of patients. Cirrhotic patients were significantly older with a significant longer duration of HCV infection than noncirrhotic patients. Laboratory parameters (AST, y-GT, y-globulin fraction) were measured significantly higher as well as significantly lower (prothrombin index, platelet count) in cirrhotic patients than in non-cirrhotic patients. Histologically, cirrhosis was confirmed in 11.1 % (8/72) and non cirrhosis in 88.9 % (64/72). Patients with macroscopically confirmed cirrhosis (n=21) showed histologically cirrhosis in 38.1 % (8/21) and histologically non-cirrhosis in 61.9 % (13/21). In contrast, patients with macroscopically non-cirrhosis (n=51) showed histologically non cirrhosis in all cases (51/51). Thirty-nine of 72 patients were treated with interferon-alfa, resulting in 35.9 % (14/39) patients with sustained response and 64.1 % (25/39) with non response. Non-responders showed significantly more macroscopically cirrhosis than sustained responders. In contrast, there were no significant histological differences between non-responders and sustained responders.
Diagnostic laparoscopy is more accurate than liver biopsy in recognizing cirrhosis in patients with chronic HCV infection. Liver biopsy is the best way to assess inflammatory grade and fibrotic stage. The invasive marker for staging, prognosis and management, and treatment outcome of chronic HCV-infected patients need further research and clinical trials. Laparoscopy should be performed for recognition of cirrhosis if this parameter is found to be of prognostic and therapeutic relevance in patients with chronic HCV infection.
评估腹腔镜检查在丙型肝炎病毒(HCV)感染患者肝硬化诊断中的潜力以及干扰素治疗的效果。
在这项回顾性研究中,对72例连续的慢性HCV感染患者进行了腹腔镜检查及腹腔镜肝活检。通过腹腔镜检查宏观分析有无肝硬化,并通过肝活检标本微观分析。比较了肝硬化患者和非肝硬化患者的临床、实验室数据以及干扰素-α治疗的效果。
腹腔镜检查显示,29.2%(21/72)的患者有肝硬化,70.8%(51/72)的患者无肝硬化。肝硬化患者的年龄显著更大,HCV感染持续时间显著更长。与非肝硬化患者相比,肝硬化患者的实验室参数(谷草转氨酶、γ-谷氨酰转肽酶、γ-球蛋白比例)显著更高,而(凝血酶原指数、血小板计数)显著更低。组织学上,11.1%(8/72)的患者确诊为肝硬化,88.9%(64/72)的患者为非肝硬化。宏观确诊为肝硬化的患者(n = 21)中,38.1%(8/21)组织学上为肝硬化,61.9%(13/21)组织学上为非肝硬化。相比之下,宏观上无肝硬化的患者(n = 51)在所有病例中组织学上均为非肝硬化(51/51)。72例患者中有39例接受了干扰素-α治疗,其中35.9%(14/39)的患者获得持续应答,64.1%(25/39)的患者无应答。无应答者宏观上肝硬化的比例显著高于持续应答者。相比之下,无应答者和持续应答者在组织学上无显著差异。
在慢性HCV感染患者中,诊断性腹腔镜检查在识别肝硬化方面比肝活检更准确。肝活检是评估炎症分级和纤维化阶段的最佳方法。慢性HCV感染患者分期、预后和管理的侵入性标志物以及治疗效果需要进一步研究和临床试验。如果发现该参数对慢性HCV感染患者的预后和治疗具有相关性,则应进行腹腔镜检查以识别肝硬化。